Australia & Australia — Therapeutic Goods Administration

Australia: Australia is the market where 4DMedical Limited's CT:VQ technology has received TGA approval, enabling its commercial deployment and expanding access to functional lung imaging across the country.

Australia — Therapeutic Goods Administration: The Australia — Therapeutic Goods Administration granted approval for 4DMedical Limited's CT:VQ technology, allowing its commercial deployment in Australia. This regulatory body's decision is crucial for market access.

Australia: Australia is the country where orelabrutinib received approval, providing a new treatment option for patients with Mantle Cell Lymphoma in the region.

Australia — Therapeutic Goods Administration: The Australia — Therapeutic Goods Administration (TGA) approved orelabrutinib in Australia, making it available as a new treatment option for Mantle Cell Lymphoma.

Australia: Australia serves as a new commercial market for Idefirix, with the TGA approval enabling access for highly sensitized kidney transplant patients. The country's registry will generate real-world evidence.

Australia — Therapeutic Goods Administration: The TGA's approval facilitated the commercial use of Idefirix in Australia, marking a regulatory success for the product in the region.

Australia: Australia is the recipient country for Optimi Health's psilocybin capsules, providing a regulated market for the treatment of treatment-resistant depression and setting a model for psychedelic medicine use.

Australia — Therapeutic Goods Administration: The Australia — Therapeutic Goods Administration in Australia oversees the Authorized Prescriber Scheme, under which Optimi Health's psilocybin is prescribed and reimbursed, facilitating patient access to psychedelic medicine.

Australia — Therapeutic Goods Administration: The Australia — Therapeutic Goods Administration (TGA) is the regulatory body in Australia whose filing was completed for the clinical trial. Its approval is essential for the trial's conduct.